A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study
drug. The study is focused on participants with previously untreated follicular lymphoma
(a type of non-Hodgkin lymphoma or NHL).
This study will be made up of two parts: Part ...
Age: 18 years - 66+
Gender: All
Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of
Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a
rare type of cancer that starts in the white blood cells and eventually can result in rashes
...
Age: 18 years - 66+
Gender: All
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas
The study is researching an experimental drug called REGN5837 in combination with another
experimental drug, odronextamab. The aim of the study is to see how safe and tolerable
the study drugs are, and to define the recommended dose for phase 2 for the combination.
...
Age: 18 years - 66+
Gender: All
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood
cell responsible for fighting infections). The purpose of this study is to assess the
change in disease activity of epcoritamab when combined with intravenous and oral
rituximab...
Age: 18 - 79 years
Gender: All
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood
cell responsible for fighting infections). The purpose of this study is to assess the
change in disease activity of epcoritamab when combined with intravenous and oral
rituximab...
Age: 18 - 79 years
Gender: All
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TN...
Age: 18 years - 66+
Gender: All
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
This study is being done to understand how many people with HIV (PWH) present for cancer care
across the AIDS Malignancy Consortium in the United States and if there are reasons that some
PWH choose to participate, or not in cancer clinical trials. Optional quality ...
Age: 18 years - 66+
Gender: All
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
The purpose of this study is to assess the safety and tolerability of zilovertamab
vedotin as monotherapy and in combination in participants with select B-cell lymphomas
including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular
lymphom...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended
Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-80948543 in Part A (Dose
Escalation) and to further characterize the safety of JNJ-80948543 at the putative ...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative
recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of
administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize
the safety of JN...
Age: 18 years - 66+
Gender: All
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type
of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional
treatment and the disease recurs in almost all patients. This study will assess how safe
and...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-cell Lymphoma That Express KIR3DL2
This is a multi-center phase Ib sutdy, which evaluates the safety and efficacy of lacutamab
monotherpy in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
Age: 18 years - 66+
Gender: All
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to
the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or
B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called
ino...
Age: 50 years - 66+
Gender: All
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood
cell responsible for fighting infections). The purpose of this study is to assess the
safety and tolerability of epcoritamab in combination with anti-neoplastic agents in
adult p...
Age: 18 years - 66+
Gender: All
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma
(MM). MM is a type of cancer of the blood. This study will also include participants with
relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
DLBCL is also a type of c...
Age: 18 years - 66+
Gender: All
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir
in patients with relapsed/refractory EBV-positive lymphomas
Age: 18 years - 66+
Gender: All
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT)
followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Age: 15 years - 66+
Gender: All
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin
and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma
(PTCL). This study will compare the experimental combination treatment of romidepsin and
or...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NH...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab
(EPKINLY™), either by itself or together with other therapies, when treating subjects
with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to
identify t...
Age: 18 years - 66+
Gender: All